Alternating modified CAPOX/CAPIRI plus bevacizumab shows promising activity in untreated unresectable metastatic colorectal cancer in a phase 2 trial.
Advancing first-line combination strategies.
doi.org/10.1038/s413...
#MetastaticColorectalCancer #CAPOX #CAPIRI #Bevacizumab #Phase2Trial
0
0
0
0